Clinical Trial Update: Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating probenecid for hereditary nephrogenic diabetes insipidus, with autosomal dominant polycystic kidney disease patients treated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease
• Nephrogenic Diabetes Insipidus

Drugs mentioned

• Probenecid (probenecid)
• Samsca (tolvaptan)

Snippet

Sponsor: Mayo Clinic | Conditions: Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus | Phase 2 | Status: COMPLETED